z-logo
open-access-imgOpen Access
Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents?
Author(s) -
Sorin J. Brener
Publication year - 2015
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.114.013279
Subject(s) - medicine , drug , intensive care medicine , cardiology , pharmacology
Coronary artery disease (CAD) remains a principal source of morbidity and mortality among adults in both the developed world and the developing world.1 Despite important advances in medical therapy for CAD, revascularization is frequently necessary. Currently, nearly 2 million percutaneous coronary interventions (PCIs) are performed in the United States and Europe, and >90% of them entail the deployment of at least 1 coronary stent.2 The introduction of metallic coronary stents (bare metal stents [BMS]) 2 decades ago resulted in a significant reduction in the immediate and long-term complications of PCI, particularly dissections, abrupt vessel closure, and need for repeat target lesion or target vessel revascularization. Abrupt vessel closure was essentially eliminated by stents.3 The incidence of target lesion and target vessel revascularization was halved from ≈20% to 25% at 1 year to 10% to 15%. Stents became further refined a decade ago by the addition of eluting antiproliferative agents embedded in durable or resorbable biopolymers (drug-eluting stents [DES]).4–6 This innovation further reduced the need for target vessel or target lesion revascularization to the single-digit range.Response by Becker and Helmy on p 2009 The persisting weaknesses of coronary stents, the propensity to provoke stent thrombosis (ST) and late neoatherosclerosis, were not modified by the introduction of DES. In fact, a sentinel report in 2004 indicated that first-generation DES are prone to late (1–12 months) and very late (>12 months) ST because of their inherent delayed endothelialization.7 Intensive research into the causes and predictors of this phenomenon resulted in the current recommendations of the various professional societies to treat patients after DES implantation with 6 to 12 months of dual antiplatelet therapy (DAPT) consisting of aspirin and an ADP (P2Y12) receptor antagonist.This article reviews the evidence supporting the continuation of DAPT for …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom